Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL628 in participants with early Alzheimer's disease is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• DNL628

Snippet

Sponsor: Denali Therapeutics Inc. | Conditions: Alzheimer Disease, Early Onset | Phase 1 | Status: RECRUITING